Sustainability in Pharma

While our sustainability approach spans every aspect of operations, our NO HARM framework reflects our cultural commitment to stewardship and influence. This means taking ownership of environmental performance, inspiring sustainable action across our network, and building trust with clients through responsible, measurable results.

Pharma and biotech companies are under increasing pressure to deliver breakthrough therapies while meeting sustainability and ESG targets. Our manufacturing processes are designed to help you meet both objectives, leveraging advanced technologies such as continuous flow processing to reduce solvent use, improve energy efficiency, and deliver consistent, scalable results for APIs, HPAPIs, and complex formulations.

We address Scope 1, Scope 2, and Scope 3 emissions across the full pharmaceutical supply chain. Our sustainability strategy focuses on reducing energy consumption, transitioning to renewable sources, and minimizing waste through prevention, reuse, recycling, and energy recovery. By applying a holistic waste management approach, we reduce environmental impact at every step—from raw material sourcing to finished drug delivery.

A sustainable CDMO must go beyond its own operations. We partner with suppliers who meet high standards for ethical and environmentally responsible sourcing. When possible, we seek alternatives to non-sustainable materials and maintain transparent conversations with partners to align on long-term green supply chain goals.

We integrate green chemistry principles into R&D and manufacturing to improve both efficiency and sustainability. This includes using catalytic processes, reducing solvent requirements, and operating at ambient conditions to lower energy consumption. Our innovations in process design not only enhance environmental performance but also reduce costs and time-to-market for our clients.

We take an active role in protecting biodiversity and water resources by responsibly managing wastewater, preventing contamination risks, and training teams to identify environmental hazards. Our facilities are designed and operated to minimize the impact on local ecosystems while maintaining compliance with regulatory standards.

Today’s pharmaceutical clients demand transparency. We provide detailed, verifiable Environmental, Social, and Governance (ESG) reporting to demonstrate performance against industry benchmarks. Our data-driven approach ensures sustainability metrics are measurable, accurate, and aligned with both client and regulatory expectations.

As a global pharmaceutical CDMO, SK pharmteco works alongside clients to advance innovation while meeting environmental responsibilities. By investing in smarter technologies, fostering transparent partnerships, and embedding sustainability into every step of development and manufacturing, we help clients meet their own sustainability goals—while accelerating the delivery of life-saving therapies to patients.